STAT3 dimerization

By Targets:	Apoptosis (1) Autophagy (1) Bacterial (1) STAT (4)
By Research Areas:	Cancer (5) Infection (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18061

Ochromycinone 3 Publications Verification (Rac)-STA-21	STAT Bacterial	Infection Cancer
Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a *STAT3* inhibitor. Ochromycinone can inhibits *STAT3* DNA binding activity, *STAT3* dimerization. Ochromycinone has anticancer and antimicrobial activity .

HY-103692

STX-0119 2 Publications Verification	STAT	Cancer
STX-0119 is a selective, orally active *STAT3* dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM .

HY-122214

AC-73 4 Publications Verification	Autophagy	Cancer
AC-73 is a first specific, orally active inhibitor of cluster of differentiation 147 (CD147), which specifically disrupts CD147 dimerization, thereby mainly suppressing the *CD147*/ERK1/2/STAT3/MMP-2 pathways. AC-73 inhibits the motility and invasion of hepatocellular carcinoma cells . AC-73 is also an anti-proliferative agent and an inducer of autophagy in leukemic cells .

HY-124843

LLL3 CLT-005	STAT Apoptosis	Cancer
LLL3 (CLT-005) is a *STAT3* inhibitor. LLL3 inhibits dimerization and phosphorylation of *STAT3, thereby preventing intraconuclear transfer of STAT3* and inhibits the expression of *STAT3* dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of *STAT3* persistent activation types of cancer .

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a *STAT3* peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library	506 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 506 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

JAK/STAT Compound Library

506 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 506 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a *STAT3* peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18061

Ochromycinone 3 Publications Verification (Rac)-STA-21	Infection Quinones Structural Classification Monophenols Microorganisms Classification of Application Fields Anthraquinones Source classification Phenols Disease Research Fields	STAT Bacterial
Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a *STAT3* inhibitor. Ochromycinone can inhibits *STAT3* DNA binding activity, *STAT3* dimerization. Ochromycinone has anticancer and antimicrobial activity .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products